NICE does not recommend Praluent (alirocumab) to treat high cholesterol-Sanofi
The National Institute for Health and Care Excellence has issued draft guidance not recommending Praluent (alirocumab)from Sanofi,for people with high cholesterol (primary hypercholesterolaemia - heterozygous-familial and non-familial) and mixed dyslipidaemia because of a lack of comparison data.
Although Praluent was effective in reducing LDL-c levels when compared with placebo, ezetimibe or statins in people with hypercholesterolaemia, the Institute was concerned that Praluent “had not been compared with the combination therapy of ezetimibe plus a statin, in the large population of people with non-familial hypercholesterolaemia”.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins